
    
      Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes
      invalidating and chronic postoperative morbidity, especially in patients with high stage
      disease. Theoretically, downstaging with neoadjuvant chemotherapy could shrink the tumour,
      making surgical treatment less extensive, thereby diminishing the chance for morbidity.
    
  